Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released for the quarter ended June 30, 2026.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results released for the quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
- Results announcement provides investors an update on operating performance and financial condition
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation released August 5, 2026, providing investors with current company strategy and operating priorities
- L(earnings) call presentation released August 5, 2026, supplying management’s accompanying investor materials
- Presentations reference anticipated actions and performance under the Tempus Agreement and Restated Agreement
- Investors should review Exhibits 99.2 and 99.3 for substantive pipeline, partnership, and financial updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $7.7M, down from $19.2M; lower Roche/Genentech recognition reflects completed prior-period project phases
- Genentech exercised first neuroscience target option, validating Recursion’s platform and initiating a small-molecule discovery program
- Collaboration economics include up to 40 programs, each with potential milestones exceeding $300M plus tiered royalties up to high single digits
- Cash $556.8M and runway into early 2028; 2026 cash operating expense guidance reduced to below $375M
- REC-7735 IND cleared, with Phase 1/2 ZINNIA trial planned for 2H26 and stated mutant selectivity above 100-fold
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.